Last updated: April 24, 2026
Who Supplies Buprenorphine HCl and Naloxone HCl for Pharmaceuticals?
What are the drug substances and what does “supplier” mean in procurement terms?
For procurement, “supplier” typically breaks into two categories:
1) API manufacturers (buprenorphine HCl and naloxone HCl drug substance)
2) Salt-form/API intermediates and finished dosage supply chains (less interchangeable, often tied to specific DMF/CEP dossiers)
This analysis covers drug substance (API) supply for Buprenorphine Hydrochloride and Naloxone Hydrochloride because these two substances are the core inputs to combination products (for example, sublingual film/tablet) and are the unit economists focus on.
Buprenorphine Hydrochloride (API) suppliers
The following supplier set is commonly observed across global API supply chains for buprenorphine hydrochloride. For each, the commercial relationship typically depends on whether the buyer needs: DMF/ASMF-covered material, specific particle specs, polymorph control, or custom grades.
| Supplier (Company) |
Typical role in supply chain |
Notes for procurement |
| Korea United Pharm. / KUP |
API manufacturer |
Often cited in regulated supply chains for opioid APIs |
| Teva API / Teva Pharmaceutical Industries supply chain |
API supply (global) |
Uses controlled manufacturing sites; often dossier-driven |
| Mylan (now Viatris) supply chain |
API and dosage-related sourcing |
API availability depends on site qualification |
| Siam Pharmaceutical |
API manufacturer |
Handles controlled opioid raw material families |
| Alchem International |
API distributor / sourcing broker |
Common for regulated procurement where sourcing is site-specific |
| Aurobindo Pharma |
API manufacturer |
Anticipate grade and salt-form constraints |
| Cipla |
API manufacturer |
Procurement often requires dossier match |
| Dr. Reddy’s Laboratories |
API manufacturer |
Availability depends on campaign manufacturing and grade |
Naloxone Hydrochloride (API) suppliers
Naloxone HCl is frequently sourced from the same tier of regulated API manufacturers, but buys are often more constrained by dossier specifics and filtration/crystallization specs.
| Supplier (Company) |
Typical role in supply chain |
Notes for procurement |
| Korea United Pharm. / KUP |
API manufacturer |
Commonly appears in regulated opioid API sourcing |
| Teva API / Teva supply chain |
API supply |
Site qualification and stability data drive qualification |
| Viatris (Mylan legacy) supply chain |
API and dosage-related sourcing |
Buyer must match required salt form and spec |
| Zydus / Cadila supply chain |
API manufacturer |
Procurement often requires DMF alignment |
| Aurobindo Pharma |
API manufacturer |
Grade depends on dosage form requirements |
| Dr. Reddy’s Laboratories |
API manufacturer |
Dossier-driven; particle and impurity profile matters |
| Hangzhou or China-based regulated API manufacturers |
API manufacturer |
Supplier qualification varies by compliance posture |
What matters when selecting a supplier for Buprenorphine HCl + Naloxone HCl?
Procurement risk in the combination opioid product supply chain concentrates in three areas.
1) Regulatory dossier alignment
- Buyers should match DMF/ASMF/CEP coverage for the exact API salt form:
- Buprenorphine hydrochloride (HCl salt)
- Naloxone hydrochloride (HCl salt)
- The key procurement control is whether the supplier’s dossier covers:
- the same salt
- spec range (assay, related substances)
- manufacturing method controls relevant to impurity profile
2) Controlled substance manufacturing constraints
Both APIs are controlled substances in many jurisdictions. Supplier qualification requires evidence of:
- licensure for production and handling
- controlled logistics (chain-of-custody)
- audit readiness (GMP compliance)
3) Specification tightness for combination products
Combination formulations (sublingual films/tablets) are sensitive to API quality attributes:
- particle size distribution and morphology controls (especially for dose uniformity and dissolution)
- impurity thresholds that may be product-specific
- stability data aligned to the target packaging system
Supplier shortlisting framework (actionable)
Use this procurement filter to narrow to the true “eligible” suppliers for both APIs:
Buprenorphine HCl
- Require: dossier match for buprenorphine HCl salt
- Require: impurity profile acceptance for the buyer’s internal spec
- Require: documented ability to supply under the buyer’s planned demand schedule
Naloxone HCl
- Require: dossier match for naloxone HCl salt
- Require: particle/crystal control suitable for the buyer’s dosage form process
- Require: stability package that supports shelf life targets
Where the supplier list typically breaks down
Even when a company lists “API” availability, the procurement fails on one of these:
- wrong salt form (freebase vs HCl salt)
- DMF/ASMF coverage for a specific region not included in the buyer’s regulatory pathway
- inability to meet required impurity set or limits tied to the buyer’s finished product
- controlled-substance compliance gaps for shipping lanes and distribution chain
Key Takeaways
- Buprenorphine HCl and Naloxone HCl are typically sourced from regulated API manufacturers with DMF/ASMF coverage and controlled-substance handling capability.
- The supplier selection pivot is dossier alignment to the exact HCl salt form, plus impurity and particle-spec control for combination dosage manufacturing.
- Shortlisting should be done on: (1) dossier match, (2) GMP and controlled handling, (3) impurity and spec capability, then (4) supply continuity.
FAQs
1) Can one supplier provide both Buprenorphine HCl and Naloxone HCl?
Yes. Several global API manufacturers and established supply-chain partners can supply both, but eligibility depends on dossier coverage for each API and the buyer’s required grades and specs.
2) What is the biggest reason suppliers get rejected for these APIs?
Mismatch against the buyer’s dossier/spec expectations, especially impurity profile targets and salt-form identity for the HCl form.
3) Do distributors count as suppliers for regulated procurement?
They can, but buyers typically treat distributors as sourcing channels. The eligibility and audit burden still attaches to the underlying API manufacturer.
4) Is the supply chain more constrained for one API than the other?
Often both are constrained similarly due to controlled-substance logistics and dossier/spec control. Practical constraints can differ by site readiness and campaign scheduling.
5) What information do buyers typically validate before placing supply orders?
Dossier coverage (DMF/ASMF/CEP), GMP site qualification, salt form (HCl), impurity and assay specs, and controlled-substance shipping and handling capability.
References
[1] FDA. “Drug Master Files (DMF) and the FDA.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/forms-drugs-and-drugsfda/drug-master-files-dmfs
[2] EMA. “CEP and assessment of drug substances.” European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmaceutical-qualifications/certificates-european-pharmaceuticals
[3] WHO. “WHO Guidelines on Submission of Documentation for Controlled Substances.” World Health Organization. https://www.who.int/
